Last reviewed · How we verify
Duotrav
At a glance
| Generic name | Duotrav |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
- Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® (PHASE4)
- Safety and Efficacy of Changing to DuoTrav From Prior Therapy (PHASE4)
- Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav (PHASE4)
- A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure (PHASE4)
- A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duotrav CI brief — competitive landscape report
- Duotrav updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI